Performance analysis of Ultragenyx Pharmaceutical (RARE)
Annual Return
Over the past 3 years, RARE has had an average annual return of -12.95%, underperforming the benchmark SPY, which returned +19.31% annual.
Over the past 5 years, RARE has had an average annual return of -19.36%, underperforming the benchmark SPY, which returned +12.55% annual.
Over the past 10 years, RARE has had an average annual return of -6.14%, underperforming the benchmark SPY, which returned +14.95% annual.
Since Jan 31, 2014, RARE has had an average annual return of -3.10%, underperforming the benchmark SPY, which returned +14.03% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +24.04% | -45.32% | -12.03% | +3.21% | -44.90% | -39.25% | +224.11% | -1.77% | -6.26% | -34.03% | -37.32% | +155.64% |
| 2014 | |||||||||||
| +3.86% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.65% | -2.83% | -10.42% | +17.85% | -3.05% | +39.48% | -14.55% | +24.04% | |||||
| 2025 | +2.29% | -0.26% | -15.64% | +7.65% | -12.70% | +6.85% | -24.87% | +9.67% | +0.41% | +15.01% | +0.44% | -33.81% | -45.32% |
| 2024 | -7.76% | +17.25% | -9.72% | -8.89% | -5.64% | +2.39% | +9.54% | +26.12% | -2.17% | -8.21% | -6.60% | -11.67% | -12.03% |
| 2023 | -2.16% | -1.85% | -9.87% | +8.90% | +13.03% | -6.55% | -6.52% | -14.68% | -3.10% | -0.70% | +9.74% | +23.09% | +3.21% |
| 2022 | -16.84% | -3.73% | +7.87% | -2.66% | -33.65% | +27.20% | -10.69% | -10.49% | -13.17% | -2.30% | -10.28% | +27.63% | -44.90% |
| 2021 | +0.12% | +2.13% | -19.56% | -1.95% | -8.90% | -6.25% | -16.28% | +20.62% | -6.34% | -6.95% | -10.36% | +11.78% | -39.25% |
| 2020 | +23.04% | +6.71% | -20.77% | +36.01% | +13.29% | +14.26% | -0.08% | +8.83% | -3.38% | +22.28% | +17.95% | +16.78% | +224.11% |
| 2019 | +13.43% | +30.05% | +8.14% | -4.85% | -16.77% | +15.61% | -5.10% | -9.61% | -21.46% | -6.16% | -1.22% | +7.71% | -1.77% |
| 2018 | +15.02% | -10.38% | +6.65% | -0.30% | +43.98% | +5.02% | +2.91% | +7.10% | -9.90% | -36.54% | +10.78% | -18.99% | -6.26% |
| 2017 | +6.69% | +13.42% | -20.33% | -5.01% | -16.36% | +15.34% | +6.78% | -13.96% | -6.66% | -13.46% | +9.54% | -8.13% | -34.03% |
Drawdown analysis of Ultragenyx Pharmaceutical (RARE)
The maximum drawdown for the RARE was -89.57%, occurring on Mar 24, 2026. This drawdown has not yet recovered.
The current RARE drawdown is -83.92%.
Since Jan 31, 2014 RARE has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 3 times
- 30% or more: 3 times
- 20% or more: 3 times
- 10% or more: 5 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -89.57% | Dec 23, 2020 | 1316 | Mar 24, 2026 | Ongoing | Ongoing | Ongoing |
| -74.79% | Jul 20, 2015 | 1172 | Mar 16, 2020 | 186 | Dec 8, 2020 | 1358 |
| -49.59% | Mar 12, 2014 | 48 | May 20, 2014 | 232 | Apr 22, 2015 | 280 |
| -18.98% | Apr 24, 2015 | 4 | Apr 30, 2015 | 8 | May 12, 2015 | 12 |
| -14.60% | Jan 31, 2014 | 3 | Feb 5, 2014 | 5 | Feb 12, 2014 | 8 |
| -8.63% | Feb 21, 2014 | 4 | Feb 27, 2014 | 7 | Mar 10, 2014 | 11 |
| -6.40% | Dec 8, 2020 | 1 | Dec 9, 2020 | 2 | Dec 11, 2020 | 3 |
| -5.97% | Jun 2, 2015 | 2 | Jun 4, 2015 | 9 | Jun 17, 2015 | 11 |
| -5.13% | Jul 7, 2015 | 1 | Jul 8, 2015 | 1 | Jul 9, 2015 | 2 |
| -5.08% | Jun 23, 2015 | 4 | Jun 29, 2015 | 2 | Jul 1, 2015 | 6 |
| -2.71% | Feb 12, 2014 | 3 | Feb 18, 2014 | 2 | Feb 20, 2014 | 5 |
| -2.65% | May 21, 2015 | 2 | May 26, 2015 | 1 | May 27, 2015 | 3 |
| -1.60% | May 28, 2015 | 2 | Jun 1, 2015 | 1 | Jun 2, 2015 | 3 |
| -1.50% | Jul 14, 2015 | 2 | Jul 16, 2015 | 1 | Jul 17, 2015 | 3 |
| -1.11% | Jul 1, 2015 | 2 | Jul 6, 2015 | 1 | Jul 7, 2015 | 3 |
| -0.38% | Dec 18, 2020 | 1 | Dec 21, 2020 | 1 | Dec 22, 2020 | 2 |